Format

Send to

Choose Destination
Lancet Respir Med. 2014 Dec;2(12):1016-26. doi: 10.1016/S2213-2600(14)70217-6. Epub 2014 Oct 28.

Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis.

Author information

1
Departments of Medicine and Anaesthesia, Cardiovascular Research Institute, University of California, San Francisco, CA, USA.
2
Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
3
Departments of Medicine and Anaesthesia, Cardiovascular Research Institute, University of California, San Francisco, CA, USA. Electronic address: michael.matthay@ucsf.edu.

Abstract

Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.

PMID:
25465643
DOI:
10.1016/S2213-2600(14)70217-6
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for eScholarship, California Digital Library, University of California
Loading ...
Support Center